Nothing Special   »   [go: up one dir, main page]

RS65562B1 - Nrf2 regulatori - Google Patents

Nrf2 regulatori

Info

Publication number
RS65562B1
RS65562B1 RS20240608A RSP20240608A RS65562B1 RS 65562 B1 RS65562 B1 RS 65562B1 RS 20240608 A RS20240608 A RS 20240608A RS P20240608 A RSP20240608 A RS P20240608A RS 65562 B1 RS65562 B1 RS 65562B1
Authority
RS
Serbia
Prior art keywords
nrf2 regulators
nrf2
regulators
Prior art date
Application number
RS20240608A
Other languages
English (en)
Inventor
Jeffrey K Kerns
James Francis Callahan
Hongxing Yan
Thomas Daniel Heightman
Charlotte Mary Griffiths-Jones
Alison Jo-Anne Woolford
Tindy Li
Shah Ami Lakdawala
Roderick S Davis
David Norton
Nicole Cathleen Goodwin
Yun Jin
Paris L Hamilton
Jeffrey Charles Boehm
Original Assignee
Glaxosmithkline Ip Dev Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Astex Therapeutics Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of RS65562B1 publication Critical patent/RS65562B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20240608A 2015-06-15 2016-06-15 Nrf2 regulatori RS65562B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175510P 2015-06-15 2015-06-15
EP20200207.7A EP3782996B1 (en) 2015-06-15 2016-06-15 Nrf2 regulators

Publications (1)

Publication Number Publication Date
RS65562B1 true RS65562B1 (sr) 2024-06-28

Family

ID=57545504

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20240608A RS65562B1 (sr) 2015-06-15 2016-06-15 Nrf2 regulatori
RS20210012A RS61302B1 (sr) 2015-06-15 2016-06-15 Nrf2 regulatori

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20210012A RS61302B1 (sr) 2015-06-15 2016-06-15 Nrf2 regulatori

Country Status (29)

Country Link
US (3) US10604509B2 (sr)
EP (2) EP3307739B1 (sr)
JP (1) JP6789995B2 (sr)
KR (1) KR102675041B1 (sr)
CN (1) CN108112251B (sr)
AU (1) AU2016279388B2 (sr)
CA (1) CA2988338C (sr)
CL (1) CL2017003226A1 (sr)
CO (1) CO2017012995A2 (sr)
CY (1) CY1123853T1 (sr)
DK (2) DK3782996T3 (sr)
DO (1) DOP2017000298A (sr)
EA (1) EA035864B1 (sr)
ES (2) ES2841574T3 (sr)
FI (1) FI3782996T3 (sr)
HR (2) HRP20240666T1 (sr)
HU (2) HUE052919T2 (sr)
IL (1) IL256297B (sr)
LT (2) LT3782996T (sr)
MA (1) MA52309A (sr)
MX (1) MX2017016405A (sr)
PE (1) PE20180799A1 (sr)
PH (1) PH12017502255A1 (sr)
PL (2) PL3307739T3 (sr)
PT (2) PT3307739T (sr)
RS (2) RS65562B1 (sr)
SI (2) SI3307739T1 (sr)
WO (1) WO2016202253A1 (sr)
ZA (1) ZA201708145B (sr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52032A (fr) 2015-06-15 2021-01-20 Astex Therapeutics Ltd Régulateurs de nrf2
EP3359532A1 (en) 2015-10-06 2018-08-15 GlaxoSmithKline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
JP2018529744A (ja) * 2015-10-06 2018-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール
EP3555088B1 (en) 2016-12-14 2021-11-24 GlaxoSmithKline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
ES2978187T3 (es) 2016-12-14 2024-09-06 Glaxosmithkline Intellectual Property Dev Heterociclos de bisarilo como activadores de NRF2
EP3555068B1 (en) * 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２アクチベーターとしてのエーテル結合トリアゾール
EP3555104B1 (en) * 2016-12-15 2021-11-24 GlaxoSmithKline Intellectual Property Development Limited Nrf2 compounds
CA3063934A1 (en) 2017-05-17 2018-11-22 Denali Therapeutics Inc. Kinase inhibitors and uses thereof
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
AU2019247653A1 (en) * 2018-04-06 2020-10-22 The Board Of Trustees Of The University Of Illinois 1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction
CR20210087A (es) * 2018-08-20 2021-05-25 Janssen Pharmaceutica Nv Inhibidores de la interacción proteína-proteína keap1-nrf2
SG11202105125XA (en) 2018-12-05 2021-06-29 Scohia Pharma Inc Macrocyclic compound and use thereof
KR20210126676A (ko) * 2019-02-15 2021-10-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
WO2020241853A1 (ja) 2019-05-31 2020-12-03 宇部興産株式会社 ベンゾトリアゾール誘導体
EP3998262A4 (en) 2019-07-03 2023-07-26 Senju Pharmaceutical Co., Ltd. NRF2 ACTIVATING LINK
CN110845435B (zh) * 2019-11-28 2021-06-08 中国药科大学 一种过氧化氢响应型Keap1-Nrf2 PPI抑制剂前药、制备方法及其医药用途
KR102590444B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR102590438B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN116669744A (zh) 2020-12-28 2023-08-29 千寿制药株式会社 Nrf2活化化合物
TW202404984A (zh) * 2022-04-28 2024-02-01 日商第一三共股份有限公司 苯并三唑化合物
TW202345792A (zh) * 2022-04-28 2023-12-01 日商第一三共股份有限公司 苯并噻吩化合物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
PT77471B (en) 1982-10-08 1986-08-19 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
ATE156116T1 (de) 1991-12-10 1997-08-15 Shionogi & Co Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
DE4220983A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CA2435829A1 (en) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
JPWO2002080899A1 (ja) 2001-03-30 2005-01-06 エーザイ株式会社 消化器疾患治療剤
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
KR100908176B1 (ko) 2001-09-21 2009-07-16 브리스톨-마이어스스퀴브컴파니 인자 Ｘａ 억제제로서의 락탐-함유 화합물 및 그의 유도체
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
US20040157919A1 (en) 2002-01-25 2004-08-12 Yong-Qian Wu Trisubstituted carbocyclic cyclophilin binding compounds and their use
AU2003281039A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Imidazole derivative
CN1798738A (zh) 2003-04-03 2006-07-05 麦克公司 作为钠通道阻滞剂的联芳基取代吡唑
WO2006044133A1 (en) 2004-09-24 2006-04-27 Axys Pharmaceuticals, Inc. Active ketone inhibitors of tryptase
EP1876179B1 (en) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
KR20100059952A (ko) 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
JP2011527345A (ja) 2008-07-07 2011-10-27 ファスジェン， インコーポレイテッド 新規な化合物、この化合物を含む医薬組成物、この化合物の使用方法、およびこの化合物の調製方法
MX2011008952A (es) 2009-02-26 2011-09-27 Merck Sharp & Dohme Activadores de guanilato ciclasa solubles.
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013067036A1 (en) * 2011-10-31 2013-05-10 Rutgers, The State University Of New Jersey Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2013122028A1 (ja) * 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
WO2013155528A2 (en) 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
US20160046616A1 (en) 2013-03-15 2016-02-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
PE20160901A1 (es) * 2013-12-18 2016-08-27 Astex Therapeutics Ltd Reguladores de nrf2
MA52032A (fr) 2015-06-15 2021-01-20 Astex Therapeutics Ltd Régulateurs de nrf2
CA2988373A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
JP2018529744A (ja) 2015-10-06 2018-10-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール
EP3359532A1 (en) 2015-10-06 2018-08-15 GlaxoSmithKline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators

Also Published As

Publication number Publication date
CO2017012995A2 (es) 2018-05-10
EP3307739A4 (en) 2019-01-23
JP6789995B2 (ja) 2020-11-25
NZ738253A (en) 2024-05-31
DK3782996T3 (da) 2024-04-22
DOP2017000298A (es) 2018-02-28
SI3782996T1 (sl) 2024-06-28
US20200079759A1 (en) 2020-03-12
AU2016279388A1 (en) 2017-12-21
LT3307739T (lt) 2021-03-10
EA035864B1 (ru) 2020-08-21
WO2016202253A1 (en) 2016-12-22
RS61302B1 (sr) 2021-02-26
CA2988338A1 (en) 2016-12-22
ES2841574T3 (es) 2021-07-08
IL256297B (en) 2020-08-31
HRP20240666T1 (hr) 2024-08-16
CN108112251B (zh) 2021-03-05
AU2016279388B2 (en) 2019-01-17
CN108112251A (zh) 2018-06-01
ES2980945T3 (es) 2024-10-03
EP3307739A1 (en) 2018-04-18
JP2018517731A (ja) 2018-07-05
PT3782996T (pt) 2024-05-27
EP3782996B1 (en) 2024-04-10
US10604509B2 (en) 2020-03-31
KR102675041B1 (ko) 2024-06-12
US20180179187A1 (en) 2018-06-28
ZA201708145B (en) 2020-01-29
SI3307739T1 (sl) 2021-03-31
EA201890052A1 (ru) 2018-08-31
HRP20202036T1 (hr) 2021-02-19
HUE066668T2 (hu) 2024-08-28
CY1123853T1 (el) 2022-03-24
CA2988338C (en) 2024-05-14
CL2017003226A1 (es) 2018-07-20
IL256297A (en) 2018-02-28
EP3782996A1 (en) 2021-02-24
DK3307739T3 (da) 2020-12-14
EP3307739B1 (en) 2020-10-07
PL3782996T3 (pl) 2024-07-15
BR112017027132A2 (pt) 2018-08-14
PL3307739T3 (pl) 2021-05-31
LT3782996T (lt) 2024-05-27
PT3307739T (pt) 2021-01-04
US20230047296A1 (en) 2023-02-16
FI3782996T3 (fi) 2024-06-26
MX2017016405A (es) 2018-05-22
KR20180018683A (ko) 2018-02-21
HUE052919T2 (hu) 2021-05-28
PH12017502255A1 (en) 2018-06-11
PE20180799A1 (es) 2018-05-09
MA52309A (fr) 2021-02-24

Similar Documents

Publication Publication Date Title
IL256297B (en) Regulators of nrf2
HK1256199A1 (zh) Nrf2調節劑
ZA201707785B (en) Beamforming
DK3256579T3 (en) Cysteinprotease
DK3250592T3 (en) Anti-transthyretin-antistoffer
GB2555736B (en) Fixing
GB201511225D0 (en) Novel structure
AU361999S (en) Ballustrade
GB201610183D0 (en) Structure
DK3133099T3 (en) Polymermodificeret polyoldispersion
PL3257657T3 (pl) Struktura zapobiegająca wyciekaniu
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201610190D0 (en) Structure
ZA201807587B (en) Polytunnel structure
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201514625D0 (en) Regulator
AU5516P (en) LEP08 Lepidosperma squamatum
AU5511P (en) PTK647 Epichloe coenophiala
GB201520684D0 (en) Aeroplanes
AU366552S (en) Nutblock
GB201515248D0 (en) Polytunnel structure
AU367131S (en) USB-charger
GB201513751D0 (en) Caft + alop
AU365008S (en) Playsuit
AU2015165V (en) PWBC12 Chamelaucium uncinatum